Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues
Jonathan G. Leung, Megan J. Ehret, Raymond C. Love, Robert O. Cotes
Topics & Concepts
MedicineClozapineDrugDrug approvalPharmacologyIntensive care medicinePsychiatrySchizophrenia (object-oriented programming)Schizophrenia research and treatmentPharmaceutical Practices and Patient OutcomesMental Health and Psychiatry